Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
Gabriel EM, Necela B, Bahr D, Vivekanandhan S, Shreeder B, Bagaria S, Knutson KL. Gabriel EM, et al. Among authors: vivekanandhan s. Res Sq [Preprint]. 2024 Apr 3:rs.3.rs-4004491. doi: 10.21203/rs.3.rs-4004491/v1. Res Sq. 2024. Update in: Sci Rep. 2024 Oct 19;14(1):24545. doi: 10.1038/s41598-024-76209-z PMID: 38645250 Free PMC article. Updated. Preprint.
Clinical factors and vascular endothelial growth factor as determinants of disease progression in Indian patients with amyotrophic lateral sclerosis.
Thomas A, Garg D, Srivastava AK, Kumar A, Pandit AK, Vibha D, Vivekanandhan S, Shukla G, Prasad K. Thomas A, et al. Among authors: vivekanandhan s. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):46-52. doi: 10.1080/21678421.2023.2256362. Epub 2023 Sep 14. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 37710422
Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study.
Dhar N, Kumar M, Tiwari A, Samanta R, Bhadoria AS, Vivekanandhan S, Saxena S, Kumar N. Dhar N, et al. Among authors: vivekanandhan s. J Neurosci Rural Pract. 2023 Apr-Jun;14(2):239-251. doi: 10.25259/JNRP_8_2022. Epub 2023 Feb 23. J Neurosci Rural Pract. 2023. PMID: 37181176 Free PMC article.
Immunotherapies in rare cancers.
Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E. Vivekanandhan S, et al. Mol Cancer. 2023 Feb 1;22(1):23. doi: 10.1186/s12943-023-01720-2. Mol Cancer. 2023. PMID: 36726126 Free PMC article. Review.
Resistance to Trastuzumab.
Vivekanandhan S, Knutson KL. Vivekanandhan S, et al. Cancers (Basel). 2022 Oct 19;14(20):5115. doi: 10.3390/cancers14205115. Cancers (Basel). 2022. PMID: 36291900 Free PMC article. Review.
68 results